Verquvo™ (vericiguat) – New drug approval

- On May 23, 2025, Teva Pharmaceuticals announced a voluntary, consumer level recall of one lot of metoclopramide 10 mg tablets because a single torsemide tablet (20 mg) was discovered in each of three individual sealed bottles of metoclopramide tablets.

- Metoclopramide was distributed nationwide between December 16, 2024 and January 1, 2025.

Product Description	NDC#	Lot# (Expiration Date)
Metoclopramide Tablets 10 mg, 100 count bottle	0093-2203-01	5420094 (9/2027)

- Metoclopramide is approved for the:

  — Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy.
  — Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

- The clinical concern regarding use of the recalled lot is lack of effect or lack of efficacy and/or potential for an adverse event(s). Teva's health hazard assessment concluded that use of the subject product lot of concern could potentially lead to severe adverse health consequences outside the known safety profile of metoclopramide if a torsemide tablet (20 mg) is ingested, although the likelihood of occurrence is remote/unlikely as metoclopramide tablets are dispensed from the original packaging, divided at pharmacy level and dispensed in smaller quantities for patient use, where the difference in tablets is likely to be noticed by the pharmacist.

- To date, Teva has not received any reports of adverse events related to this recall.

- Anyone with the affected lots on hand should stop distribution and quarantine product.

- Contact Teva Medical Information by phone at **1-888-838-2872** or by email at **druginfo@tevapharm.com** for questions regarding this recall.